Sequoia Capital, founded in 1972 and based in Menlo Park, California, is a prominent venture capital firm that invests in early to growth stage companies across various sectors, including technology, healthcare, financial services, and consumer services. The firm specializes in supporting startups and emerging growth companies, typically investing between $100,000 and $1 million in seed companies, $1 million to $10 million in early ventures, and $10 million to $100 million in growth investments. Sequoia Capital operates globally, with a presence in regions such as Israel, China, and Southeast Asia, and has built a diverse portfolio that includes notable companies like Airbnb, Alibaba, and JD.com. The firm emphasizes a partnership approach with entrepreneurs, leveraging decades of experience to guide them from initial concept through to public offering and beyond.
TH International Ltd is the parent company responsible for operating Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Incorporated in 2018 and based in Shanghai, the company provides a range of offerings, including freshly brewed coffee, tea, baked goods, sandwiches, and other food products. Tim Hortons China focuses on delivering a unique coffee experience, with menu items tailored to local tastes, such as shrimp sandwiches and salads. In addition to its Tim Hortons operations, TH International also manages the Popeyes brand within mainland China. The company's primary revenue is derived from its Tim Hortons segment, reflecting its commitment to expanding the brand's presence in the region.
Eddingpharm, established in 2001, is a pharmaceutical company focused on supplying high-quality patented and branded drugs to the Chinese healthcare market. The company aims to bridge the gap between Chinese patients and global medicines by acquiring classic branded medications from multinational corporations and introducing innovative patented drugs. Eddingpharm has rapidly expanded its operations across China, deploying nearly 1,000 professional representatives in 30 provinces, with access to over 19,000 hospitals and 20,000 pharmacies. Its collaborations with multinational pharmaceutical companies and leading research institutions have enriched its product portfolio, particularly in therapy areas such as oncology, cardiovascular, respiratory, and renal diseases. A notable product in its line is Vascepa®, a prescription medication that lowers triglyceride levels without raising LDL cholesterol. Eddingpharm has been granted development and commercialization rights for Vascepa® in mainland China, Hong Kong, Macau, and Taiwan, and is currently conducting clinical trials to support its regulatory registrations. The company's commitment to professionalism, excellence, responsibility, and persistence underpins its mission to enhance treatment options for patients in China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.